Schering

Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS

CAMBRIDGE, Mass. and BERLIN /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd Congress of ...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option to license a specified BiTE antibody...

BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company

...cluding Beth Israel Deaconess Medical Center, Children's Hospital Boston, Genzyme Corporation, Centocor, Inc. (a Johnson & Johnson subsidiary) and schering Corporation. Each of BioMed's other top ten tenants publicly announced significant capital raising transactions in recent months: On August 3...

PharmaForce Inc. Receives FDA Approval for First Generic of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP

... and Betamethasone Acetate Injectable Suspension, USP, a generic version of schering Corporation's Celestone(R) Soluspan(R). PharmaForce's product is ma... information. Celestone(R) Soluspan(R) is a registered trademark of schering Corporation. Media Contact: Nicholas Uchyn Vice Preside...

EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors

... MRI imaging business, including a commercial MRI imaging drug in Europe, (MS-325), formerly marketed as Vasorist(R), gadofosveset trisodium, by Bayer schering Pharma.) EPIX also has collaborations with several leading pharmaceutical and research foundations. The intellectual property, regulatory do...

MEDRAD Recognized by the Premier Healthcare Alliance for Commitment to Healthcare Quality Improvement and Innovation

...activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer schering Pharma. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at ...

Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII

...obal clinical experience with rFVIII-FS," said Georg Lemm, M.D., Ph.D., vice president, Global Clinical Development, and head, Hematology Group, Bayer schering Pharma. "It is particularly noteworthy that a low rate of inhibitor formation was observed in this analysis of data pooled from post-marketing surveil...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...s corresponding Graph/Chart) II-13 Roche & schering - Dominant Players in HCV Therapeutics Market II-14 HCV Drugs from Roche & schering II-14 Partnerships in R&D Become Order of ...ibavirins offered by Major Players - Roche and schering for the Years 2003 through 2008 (In US$ Millio...

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...utic needs not addressed by existing drugs. The global marketplace is characterized by participants such as Abbott Laboratories, Amgen Inc., Bayer schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-...

Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option to license a specified BiTE antibody...

Schering in Medical Technology

Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data

SEATTLE, June 18 /PRNewswire-FirstCall/ -- On Wednesday, June 18, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC ; MTA) management team will host a conference call to discuss agreement with Bayer Schering Pharm...

Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis

CAMBRIDGE, Mass., and BERLIN, Sept. 26 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for th...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

...r 2009 10-Q, filed May 1, 2009. References: 1. ASMANEX (R) Package Insert. Schering-Plough K.K. 2. ASMANEX (R) U.S. Package Insert. schering Corporation. ...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option to license a specified BiTE antibody...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option to license a specified BiTE antibody...

Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data

...ms to allow for significant drug uptake in the treated vessel." Bayer schering Pharma AG (Berlin, Germany) is the owner of the Paccocath technology and is...icals divisions. The pharmaceuticals business operates under the name Bayer schering Pharma. Bayer HealthCare's aim is to discover and manufacture products that...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...nflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, ...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

...nflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, ...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

...omed, and the first clinical trial with MT203 is expected to be initiated in the first half of 2009. Micromet has granted an exclusive option to Bayer schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, ...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...nflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, ...

Schering in Biological News

ASBMB taps 8 scientists for top awards

...Investigator and Professor at the University of Massachusetts Medical School, will be presented with the Schering-Plough Research Institute Award. The schering Plough Award was established to recognize young investigators for outstanding research at an early stage of their careers. A pioneer in the study of R...

Male contraception: One door opens, another closes

...ew it was going to be either a strike out or a home run," says Amory. "It was a big disappointment." Unbeknownst to Amory, pharmaceutical giant schering was simultaneously testing miglustat in rabbits and another strain of mice, and found the same results--contraception in the first strain of mice, but...

Morphine for Chest Pain Increases Death Risk

...rence to the ACC/AHA treatment guidelines and patient outcomes. The CRUSADE registry is funded by Millennium Pharmaceuticals, Cambridge, Mass., and schering Corp, Kenilworth, N.J. Bristol-Meyers Squibb/Sanofi Pharmaceuticals Partnership, NY, provided an unrestricted grant in support of CRUSADE. ...

Schering in Biological Technology

Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG

BETHESDA, Md., Jan. 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced the signing of an option, collaboration and license agreement ...

GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years

ST. JOSEPH, Mich., Jan. 6 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and high quality manually curated databases for systems biology and pathway analysis , today announced that Bayer Schering Pharma AG has renewed its MetaCore licenses for another three years. Bayer Scherin...

CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application

Access to data may provide potential for label expansion in the U.S. SEATTLE, June 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTA) announced today an agreement with Bayer Schering Pharma to gain access to Bayer's phase III Zevalin(R) ([90Y]-ibritumomab tiuxet...

Micromet Closes $80.5 Million Public Offering of Common Stock

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option until January 2010 to license a spec...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option to license a specified BiTE antibody...

Micromet Announces Pricing of Public Offering of Common Stock

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option until January 2010 to license a spec...

Micromet Announces Public Offering of Common Stock

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option until January 2010 to license a spec...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... has entered into an option, collaboration and license agreement with Bayer schering Pharma AG under which Bayer schering Pharma was granted an exclusive option to license a specified BiTE antibody...

REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients

...1, 2009. References: REMERON(R) Package Insert. Schering-Plough K.K. REMERON(R) (summary of product characteristics). schering Corporation. ...

Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

...uibb, Glaxo SmithKline, Wyeth, Onyx Pharmaceuticals Inc., Merck & Co. Inc, KAI Pharmaceuticals Inc, Celgene Corporation, Sanofi-Aventis, and Bayer schering Pharma AG, among others. The report titled "Small Molecule Kinase Inhibitors: A Global Strategic Business Report" announced by Global ...